Summit Therapeutics Inc. (SMMT) intrinsic value & 10-year financials
Summit Therapeutics Inc. (SMMT) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- £14.63
- Market cap
- £10.9B
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- -21.1%
- ROIC (10-yr avg)
- -206.2%
- Free cash flow (FY2025)
- -£323.6M
SMMT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -£1.1B | -£1.44 | -£323.6M | — | -292.4% |
| FY2024 | £0 | -£221.3M | -£0.31 | -£142.2M | — | -113.9% |
| FY2023 | £0 | -£614.9M | -£0.99 | -£76.9M | — | -301.3% |
| FY2022 | £705.0K | -£78.8M | -£0.41 | -£42.2M | -10225.4% | -51.1% |
| FY2021 | £1.8M | -£88.6M | -£0.48 | -£72.9M | -4764.3% | -655.5% |
| FY2020 | £860.0K | -£52.7M | -£0.38 | -£48.5M | -6185.2% | -404.1% |
| FY2019 | £57.1M | £10.9M | £0.08 | -£35.3M | 9.4% | 20.0% |
| FY2018 | £25.4M | -£7.1M | -£0.04 | -£15.0M | — | 201.4% |
| FY2017 | £2.3M | -£21.4M | -£0.04 | £12.1M | — | -339.6% |
| FY2016 | £0 | -£20.1M | — | -£17.2M | — | -125.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in GBP.
Executive summary
Summit Therapeutics Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Summit Therapeutics Inc. has historically struggled to out-earn its cost of capital, averaging just -30.3% ROIC.
Summit Therapeutics Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Summit Therapeutics Inc. is modeled at -21.1% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-2.29 per share.